SLC5A2 and type 2 diabetes mellitus: Recently, several new classes of drugs have been developed for treating type 2 diabetes, which include dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and SGLT2 antagonists.